首页|期刊导航|中国药物经济学|治伤胶囊与伤科接骨片治疗急性软组织损伤的药物经济学评价

治伤胶囊与伤科接骨片治疗急性软组织损伤的药物经济学评价OA

Pharmacoeconomic Evaluation of Zhisang Capsules and Orthopedic Bone Tablets in the Treatment of Acute Soft Tissue Injuries

中文摘要英文摘要

目的 评价治伤胶囊与伤科接骨片治疗急性软组织损伤的经济性.方法 根据本研究的Meta分析结果,以医疗系统为研究角度,采用决策树模型对治伤胶囊与伤科接骨片治疗急性软组织损伤进行成本-效果分析,并进行敏感性分析.结果 Meta分析结果显示,治伤胶囊治疗急性软组织损伤的有效率为95.24%高于伤科接骨片84.38%(P<0.05);成本-效果分析结果显示,与伤科接骨片比较,治伤胶囊治疗急性软组织损伤成本低,效果优,为具有绝对经济优势的治疗方案;为进一步验证结果的可靠性与稳定性,进行单因素敏感性分析结果显示,基础分析的结果稳定性良好.结论 治伤胶囊在治疗急性软组织损伤中,凭借其良好的安全性、显著的有效性以及突出的经济性,为临床治疗急性软组织损伤提供了一种优质、高效且经济的药物选择.

Objective To evaluate the economic viability of Zhishang Capsules and Orthopedic Bone Tablets in the treatment of acute soft tissue injuries.Methods Based on the meta-analysis results of this study,from the perspective of the medical system as the research Angle,the decision tree model was used to conduct a cost-effectiveness analysis of the treatment of acute soft tissue injuries with Zhishang Capsules and Orthopedic bone Tablets,and a sensitivity analysis was also carried out.Results The results of the meta-analysis showed that the effective rate of Zhishang Capsules in treating acute soft tissue injuries was 95.24%,which was higher than that of Orthopedic bone Tablets at 84.38%(P<0.05).The cost-effectiveness analysis results show that compared with orthopedic bone tablets,Zhishang Capsules have lower costs and better effects in treating acute soft tissue injuries,and are a treatment plan with absolute economic advantages.To further verify the reliability and stability of the results,a single-sensitivity analysis was conducted.The results showed that the stability of the basic analysis results was good.Conclusion Zhishang Capsules,with their excellent safety,significant efficacy and outstanding economy,offer a high-quality,efficient and economical drug option for the clinical treatment of acute soft tissue injuries.

张艳玲;唐建飞;范仲姝

中国中医科学院西苑医院,北京 100091杭州朱养心药业有限公司,杭州 310018杭州朱养心药业有限公司,杭州 310018

医药卫生

急性软组织损伤治伤胶囊伤科接骨片成本-效果分析

Acute soft tissue injuryZhishang CapsulesOrthopedic Bone TabletsCost-effectiveness analysis

《中国药物经济学》 2025 (8)

29-32,66,5

10.12010/j.issn.1673-5846.2025.08.005

评论